louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02751684: EUROpE-RSI (EURopean Online Evaluation RSI Study)
Official title: EUROpE RSI-Study (EURopean Online Evaluation) - Pan-european Online-survey About Rapid Sequence Induction (RSI) by Anesthetists
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Rapid Sequence Induction
Keywords: Rapid Sequence Induction
European
Evaluation
EUROpE RSI
Standards
RSI
Lead sponsor: Universitätsklinikum Köln
Sponsor class: OTHER
First posted: 2016-04-26
Enrollment: 1500
Sex: ALL
Minimum age (years): 25
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Emergency physicians from europe; e.g. members of the European Society of Anaestesiology

Brief summary: The investigators want to identify and show differences in standards and procedures of in-hospital rapid sequence induction by collecting data with an online survey for anaesthetist in Europe.

Detailed description: The study is designed as a web-based online survey for anaesthetist in Europe. They will be invited via mail, as members of the European Society of Anaesthesiology (ESA), the participation is voluntary.

The survey contains 30 items about the standards and procedures of in-hospital rapid sequence induction (RSI). There will be a selection of possible answers, only a few items contains free-text answers.

The study collects only personal data to age, country, gender and level of training.

The collected data should identify differences in the procedures of RSI.

Eligibility criteria: Inclusion Criteria:

* Emergency physician

Exclusion Criteria:

* None Emergency physician

Primary outcomes:
measure: Differences in the procedure of the RSI (Rapid sequence induction)
timeFrame: 04.30.2016-10.30.2016
Secondary outcomes:
Other outcomes:
Locations:
city: Cologne
country: Germany
facility: University hospital of Cologne
state: NRW
Study officials:
References:
Clinical trial NCT00000584: Transfusion-Transmitted Cytomegalovirus Prevention in Neonates
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Blood Transfusion
Cytomegalovirus Infections
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Sponsor class: NIH
First posted: 1999-10-28
Sex: ALL
Maximum age (years): 1
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Primary purpose: PREVENTION

Brief summary: To evaluate the capacity of intravenously administered cytomegalovirus (CMV)-immune globin (CMVIG) to immunize high risk premature infants against CMV infections.

Detailed description: BACKGROUND:

Premature infants who require multiple blood transfusions have a 15-30 percent incidence of cytomegalovirus infections. Many of these infections result in severe disease, with a mortality of about 20 percent. In theory, the infection could be avoided by using blood and blood products exclusively from CMV antibody negative donors. The use of such blood is impractical because it would require the rejection of approximately 40 percent of all blood donors. Studies had suggested that passively acquired antibody could reduce the incidence of disease in exposed neonates. This provided the rationale for the use of passive immunization with hyperimmune globin in premature infants likely to require multiple transfusions. Lots of high titer CMV immune globulin suitable for intravenous administration were prepared using a technique of screening outdated blood bank plasma for units with high levels of antibody to CMV.

DESIGN NARRATIVE:

Randomized, double-blind. Subjects received either prophylactic CMVIG-intravenously or a placebo. Infants were followed for up to 12 weeks after discharge. Total sample size was expected to be 650.

The study completion date listed in this record was inferred from last publication listed in the Citations section of this study record.

Eligibility criteria: Neonates at high risk for transfusion-transmitted CMV infection. The neonates were either premature, of low birth weight, or had respiratory distress requiring the presence of an umbilical catheter.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Snydman DR. Prevention of cytomegalovirus-associated diseases with immunoglobulin. Transplant Proc. 1991 Jun;23(3 Suppl 3):131-5, discussion 135. No abstract available.
citation: Snydman DR, Werner BG, Meissner HC, Cheeseman SH, Schwab J, Bednarek F, Kennedy JL Jr, Herschel M, Magno A, Levin MJ, et al. Use of cytomegalovirus immunoglobulin in multiply transfused premature neonates. Pediatr Infect Dis J. 1995 Jan;14(1):34-40. doi: 10.1097/00006454-199501000-00007.
Clinical trial NCT06758284: Effect of Laughter Yoga on Surgical Fear and Anxiety in Patients Applied Before Ureteroscopy
Official title: Effect of Laughter Yoga on Surgical Fear and Anxiety in Patients Applied Before Ureteroscopy: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Ureteroscopy
Kidney Stones
Lead sponsor: Kocaeli University
Sponsor class: OTHER
First posted: 2025-01-03
Enrollment: 92
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Surgical fear is a situation where a person experiences excessive fear of surgical procedures. This fear can negatively affect the person's normal life and is usually more intense in the pre-operative period. The causes of surgical fear include factors such as previous negative surgical experiences, lack of sufficient information, post-operative pain and complications. In addition, factors such as age, gender, and level of education can also affect fear. This fear can lead to physical and psychological problems along with stress; symptoms such as increased heart rate, dizziness, and muscle tension can be seen. Methods such as cognitive-behavioral therapy, meditation, and hypnosis can be used in the treatment of surgical fear. In addition, anxiety can also arise from thinking about the surgical procedure, post-operative complications, fear of anesthesia, or pain. High-risk surgeries and past negative experiences can increase anxiety. High anxiety before surgery can lead to psychological and physical problems. Nurses should offer anxiety-reducing techniques (breathing exercises, relaxation) by taking into account the needs of patients. In addition, having relatives with the patient can help relieve anxiety. Laughter yoga is considered an effective complementary therapy to reduce surgical fear and anxiety. Developed in India in 1995, this method involves simulating laughter with yoga breathing techniques. Laughter yoga relaxes muscles, increases pain threshold, and improves overall psychological well-being. This study aims to evaluate the effects of laughter yoga on patients undergoing ureteroscopy.


Eligibility criteria: Inclusion Criteria:

It will be applied to patients who agree to participate in the study, are scheduled to undergo ureteroscopy in a urological surgery clinic, have no hearing or vision problems, are over the age of 18, understand and speak Turkish, are literate, and can communicate.

Exclusion Criteria:

Patients with mental retardation and any psychiatric disorder, alcohol or drug addiction, hypertension or heart disease, hernia, glaucoma will be excluded.

Primary outcomes:
measure: Surgical Fear
timeFrame: 40 minutes before the ureteroscopy procedure, 5 minutes before the ureteroscopy procedure
Secondary outcomes:
measure: Anxiety
timeFrame: 40 minutes before ureteroscopy, 5 minutes before ureteroscopy
Other outcomes:
Locations:
city: Samsun
country: Turkey
facility: Samsun Gazi State Hospital
Study officials:
References:
Clinical trial NCT00266084: Clinical Trial for the Use of a Novel Cell Collector Device to Retrieve Cells From the Uterine Cervix
Official title: Double-Blinded Multicenter Clinical Study Assessing the Equivalence of the InPath Cervical Cell Collector to the Standard Endocervical Brush and Spatula in Patients Seeking Primary Pap Screening or Follow-up Screening
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Uterine Cervical Dysplasia
Uterine Cervical Intraepithelial Neoplasia
Uterine Cervical Neoplasia
Uterine Cervical Cancer
Keywords: Cervix
Uterus
Dysplasia
Cancer
Collector
Lead sponsor: University Hospitals Cleveland Medical Center
Sponsor class: OTHER
First posted: 2005-12-15
Enrollment: 85
Sex: FEMALE
Minimum age (years): 14
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no

Brief summary: This study tested the safety and performance of a new cell collector device and compared the results to those obtained with the current existing device that are being used routinely

Detailed description: This study tested the feasibility, safety and efficacy of the new e2TM Collector, and compared its performance with the standard method for obtaining cervical cells for Pap test of endocervical cytobrush and Ayer's Spatula

Eligibility criteria: Inclusion Criteria:

Women ages \>14 being followed for a previous abnormal Pap All patients will have signed an Informed Consent form prior to being enrolled in this study

Exclusion Criteria:

Patients who have had a hysterectomy

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University Hospitals of Cleveland, Case Western Reserve University
name: George I Gorodeski, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02869984: Clinical Trial Assessing 5-HT3 Receptor Antagonist (Ramosetron) for the Treatment of Anterior Resection Syndrome
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: EARLY_PHASE1
Conditions: Anterior Resection Syndrome
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
Collaborators: name: Dong-A ST
First posted: 2016-08-17
Enrollment: 100
Sex: MALE
Minimum age (years): 19
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Poor functional outcomes has been reported inevitably, and up to 90% of the patients have experienced bowel habit changes after sphincter-saving surgery for rectal cancer. But, currently there has been no specific treatment for ARS and symptom based empirical management is tried Recently, 5-HT3 receptor antagonists can be used for treatment of IBS-D, and has been revealed to be slowing the bowel movement and improving stool consistency and urgency.

We performed the clinical trial with using ramosetron (Irribow®) for the treatment of ARS


Eligibility criteria: Inclusion Criteria:

* The patients who undergo sphincter saving surgery for rectal cancer

Exclusion Criteria:

* recurred rectal cancer
* rectal cancer with distant metastasis
* permanent stoma formation
* postoperative concurrent chemoradiotherapy
* uncontrolled medical disease
* inflammatory bowel disease
* uncontrolled constipation
* preoperative incontinence (LARS score, more than 20)
* allergic to intervention drug

Primary outcomes:
measure: low anterior resection syndrome score
timeFrame: 4 weeks
Secondary outcomes:
measure: Quality of Life score
timeFrame: 4 weeks
Other outcomes:
Locations:
Study officials:
References:
citation: Ryoo SB, Park JW, Lee DW, Lee MA, Kwon YH, Kim MJ, Moon SH, Jeong SY, Park KJ. Anterior resection syndrome: a randomized clinical trial of a 5-HT3 receptor antagonist (ramosetron) in male patients with rectal cancer. Br J Surg. 2021 Jun 22;108(6):644-651. doi: 10.1093/bjs/znab071.
Clinical trial NCT03848884: Impact of Adherence Education and Monitoring on Community Pharmacy Star Ratings and Patient Satisfaction
Official title: Impact of Adherence Education and Monitoring on Community Pharmacy Star Ratings and Patient Satisfaction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Adherence, Patient
Lead sponsor: Virginia Commonwealth University
Sponsor class: OTHER
First posted: 2019-02-21
Enrollment: 34
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Does monthly adherence monitoring and education by a pharmacy resident impact Kroger star ratings, compared to the current standard?

Detailed description: To evaluate if a monthly adherence monitoring and education service impacts the percent of patients adherent to oral diabetes and renin-angiotensin system antagonists (RASA) medications based on star ratings. It will also evaluate patient satisfaction of the adherence monitoring and education service, using a standard questionnaire.

Eligibility criteria: Inclusion Criteria:

1. 18 years or older
2. Patients pre-identified by Kroger analytics in ClinicalQ - Patients with PDC \< 80%
3. Patient taking oral diabetes medications and/or RASA medications (ACE-I, ARB, direct renin inhibitor)

Exclusion Criteria:

1. Patients who are enrolled in MedSync or Autorefill program
2. Patients who are lost to follow-up
3. Incomplete/missing documentation of an encounter
4. Prisoners, children

Primary outcomes:
measure: Adherence in oral diabetes medications determined by star ratings
timeFrame: Baseline to 6 months
measure: Adherence in renin-angiotensin system antagonists (RASA) medications determined by star ratings
timeFrame: Baseline to 6 months
Secondary outcomes:
measure: Change in proportion of days covered (PDC)
timeFrame: Baseline to 6 months
Other outcomes:
measure: Satisfaction with education and monitoring service
timeFrame: 6 months
Locations:
city: Richmond
country: United States
facility: Virginia Commonwealth University
state: Virginia
Study officials:
affiliation: Virginia Commonwealth University
name: Jean-Venable Goode, PharmD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01727284: MR-Guided Cryoablation of Prostate Bed Recurrences
Official title: Technical Success, Safety, and Short and Long-term Efficacy for MR-Guided Cryoablation of Prostate Bed Recurrences
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Prostate Tumors
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2012-11-15
Enrollment: 107
Sex: MALE
Minimum age (years): 30
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this research is to see if MR-guided cryoablation can effectively treat prostate tumor recurrences.


Eligibility criteria: Inclusion Criteria:

* Patients with "biopsy proven" soft tissue tumor recurrences of prostate fossa
* Surgery is not a desirable alternative therapy at the time of enrollment
* Radiation therapy has failed or not indicated or can be safely postponed
* Tumor size is \< 5 cm at its largest diameter
* Tumor does not encompass the rectal wall or external urethral sphincter
* Patient is able to undergo MRI

Exclusion Criteria:

* N/A

Primary outcomes:
measure: Evaluation of target lesion at 3-6, 12, 24, and 36 month imaging follow-up
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: David Woodrum, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01464684: Body Composition of Infants: Follow-up to Placenta and Cord Blood Analyses
Official title: Body Composition of Infants: Follow-up to Placenta and Cord Blood Analyses
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Infant Body Composition and Metabolism
Lead sponsor: University of Arkansas
Sponsor class: OTHER
First posted: 2011-11-03
Enrollment: 0
Sex: ALL
Minimum age (years): 3
Maximum age (years): 21
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: infants age 12 months (+/- 9 months)

Brief summary: Investigators will characterize the body composition and metabolism of infants born from lean, overweight or obese mothers from whom they had previously obtained a placenta and/or cord blood as part of the earlier placenta and cord blood study (#111576)


Eligibility criteria: Inclusion Criteria:

* mother's prior participation in study #111576 with successful collection of placenta
* infant age 12 months (+/- 9 months)

Exclusion Criteria:

* mother did not participate in study #111576
* mother did participate in study #111576, but collection of placenta was not successful
* infant not age 12 months (+/- 9 months)

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University of Arkansas
name: Aline Andres, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00678184: The Effect of Atorvastatin on Renal Function in Healthy Subjects During Normal and High Sodium Intake
Official title: The Effect of Acute HMG-CoA-Reductase Inhibition (Atorvastatin) on Renal Sodium Excretion, Renal Hemodynamics, Tubular Function and Vasoactive Hormones in Healthy Subjects During Normal and High Sodium Intake
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Healthy Subjects
Keywords: Atorvastatin
healthy
sodium excretion
hemodynamics
tubular function
Lead sponsor: Regional Hospital Holstebro
Sponsor class: OTHER
First posted: 2008-05-15
Enrollment: 23
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: We wanted to test the hypothesis that acute treatment with atorvastatin changes renal sodium handling, renal hemodynamics, tubular function and vasoactive hormones in healthy humans during normal and high sodium intake.

Detailed description: We wanted to test the hypothesis that acute treatment with atorvastatin changes renal sodium handling, renal hemodynamics, tubular function and vasoactive hormones in healthy humans during normal and high sodium intake.

We wanted to analyze if changes in renal hemodynamics, tubular function, hormones, blood pressure and HR under acute treatment with atorvastatin depends on sodium intake.

Eligibility criteria: Inclusion Criteria:

1. Age 20-50 yr
2. BMI\<30
3. Females had to use oral contraceptive treatment or IUD.

Exclusion Criteria:

1. Clinical signs or history of disease of the heart, lungs, kidneys, liver, brain or endocrine organs
2. Abnormal laboratory blood tests (hemoglobin, sodium, potassium, albumin, creatinine, blood glucose, bilirubin, alanin amino transferase, alkalic phosphatase)
3. Albuminuria or glucosuria
4. cancer
5. arterial hypertension
6. alcohol abuse
7. medical treatment, except contraceptives
8. pregnancy or breast feeding
9. blood donation one month before the study.

Primary outcomes:
measure: Glomerular filtration rate, clearance of sodium and lithium, fractional excretion of sodium and lithium, U-AQP-2, total sodium excretion, free water clearance
timeFrame: 6 months
Secondary outcomes:
measure: AVP, Ang-II, Aldosterone, ANP, BNP, PRC, BP and HR.
timeFrame: 6 months
Other outcomes:
Locations:
city: Holstebro
country: Denmark
facility: Department of Medical Research, Holstebro Hospital
city: Holstebro
country: Denmark
facility: Medical Research
Study officials:
affiliation: Dept. of medical reaserch, Holstebro Hospital, Denmark
name: Erling B. Pedersen, Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01774084: Insulin Sensitivity and Beta Cell Function After Carbohydrate Loading in Hip Replacement Surgery
Official title: Insulin Sensitivity and Beta Cell Function After Carbohydrate Loading in Hip Replacement Surgery: A Randomised Doubled-blinded Control Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Insulin Sensitivity
Keywords: Insulin sensitivity
Beta cell function
Carbohydrate preload
Elective hip replacement
Double-blind randomized control study
Lead sponsor: Karolinska Institutet
Sponsor class: OTHER
First posted: 2013-01-23
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether preload of carbohydrate or water before elective hip replacement improve insulin sensitivity and or beta cell function in human.


Eligibility criteria: Inclusion Criteria:

* Elective hip replacement

Exclusion Criteria:

* Known diabetes mellitus
* Kidney failure (creatinine clearance \<40 ml/min
* Liver failure (aspartate and alanine aminotransferases x 2 above reference)
* Hb \<110 g/l
* Ongoing severe bacterial or viral infection
* Malignancies
* Psychiatric disease

Primary outcomes:
measure: Change in Insulin Sensitivity
timeFrame: Morning before surgery and up to two days after surgery
Secondary outcomes:
measure: Change in Beta Cell Function
timeFrame: Morning before surgery and up to two days after surgery
Other outcomes:
Locations:
city: Stockholm
country: Sweden
facility: Södersjukhuset AB
city: Södertälje
country: Sweden
facility: Södertälje hospital
Study officials:
affiliation: Karolinska Institutet
name: Thomas Nyström, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Ljunggren S, Hahn RG, Nystrom T. Insulin sensitivity and beta-cell function after carbohydrate oral loading in hip replacement surgery: a double-blind, randomised controlled clinical trial. Clin Nutr. 2014 Jun;33(3):392-8. doi: 10.1016/j.clnu.2013.08.003. Epub 2013 Aug 15.
Clinical trial NCT06152484: Evolution of a Novel Optical Coherence Tomography Based Index in Diagnosing Keratoconus
Official title: A Study on Evaluating the Consistency of CASIA2, Pentacam, and Corvis ST Measurement Parameters and the Diagnostic Efficacy of Early Keratoconus
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Scansys, Pentacam, Keratoconus, Subclinical Keratoconus
Keywords: Scansys, Pentacam, Keratoconus, subclinical keratoconus
Lead sponsor: Tianjin Eye Hospital
Sponsor class: OTHER
First posted: 2023-11-30
Enrollment: 200
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients premedicated for refractive surgery

Brief summary: Comparison of corneal topography based on oct OCT principle (CASIA2) with Pentacam and Scheimpflug-based biomechanical devices (Corvis ST) in screening and diagnosing keratoconus; and evaluation of the consistency with Pentacam in measuring corneal parameters (such as curvature and thickness).


Eligibility criteria: Inclusion Criteria:

1. Best corrected visual acuity (BCVA) ≥ 20/20;
2. No other eye diseases except myopia and astigmatism;
3. The cornea was transparent, and there was no cloud or pannus;

Exclusion Criteria:

1. The presence of ocular diseases other than myopia and keratoconus;
2. Ocular trauma;
3. Previous ocular surgery; 4 Patients were required to stop wearing soft contact lenses for at least 2 weeks and rigid contact lenses for at least 4 weeks before examination; 6. Pregnant and lactating women;

Primary outcomes:
measure: screening and diagnosis ability
timeFrame: one year
Secondary outcomes:
measure: Measurement consistency
timeFrame: one year
Other outcomes:
Locations:
city: Tianjin
country: China
facility: Tiajin Eye Hospital
state: Tianjin
Study officials:
affiliation: Tiajin Eye Hospita
name: Yan Wang, Prof
role: STUDY_CHAIR
References: